Worth reading
46Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
3.9
%Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Third quarter2024年４月１日～2024年12月31日Non-consolidated (standalone)Japanese GAAPNet Sales5,806¥ millionYear on year +3.9%
Operating profit-341¥ million
Ordinary income-297¥ million
Net income attributable to owners of the parent-19¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Net income per share−¥0.55
Financial position at period-end
Total assets15,103¥ million
of which net assets 11,885 ¥ millionEquity ratio 78.7%vs. prior year-end +0.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenue
Pharmaceuticals2,506,59943.2%+0.7%
Healthcare Business1,824,31131.4%+3.1%
Global Business1,342,02223.1%+12.0%
Real estate leasing133,9382.3%+4.2%
Segment profit
Pharmaceuticals-878,572
Healthcare Business308,557
Global Business182,205
Real estate leasing46,245
Outlook and shareholder returns
Full-year earnings forecast
Net SalesUndecided
Operating profitUndecided
Ordinary incomeUndecided
Net incomeUndecided
Annual Dividend Forecast¥3.00 → Undecided
Factors Behind Changes in Business Performance
売上高は、医薬事業の製品供給停止等による減少があったものの、ジェネリック新製品の上市、ヘルスケア事業のブランド育成、グローバル事業の乳酸菌原料等の増加により増加した。営業損失の拡大は、人件費等の増加による販売費及び一般管理費の増加による。
Disclosure regarding the going concern assumption
No applicable matters ("There are no applicable matters")
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥170,562 thousand / Extraordinary loss Loss on disposal of non-current assets ¥1,936 thousand, Office relocation expenses ¥1,314 thousand
Depreciation and amortization¥316,831 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End34,838,325 shares
Treasury Shares at Period-End132,023 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 2024年４月１日～2024年12月31日 |
| Net Sales | ¥5,806 million (YoY +3.9%) |
| Operating profit | ¥-341 million |
| Ordinary income | ¥-297 million |
| Profit attributable to owners of the parent | ¥-19 million |
| Net income per share | −¥0.55 |
| Equity ratio | End of the current fiscal period 78.7% / End of previous period 78.0% |
| Total assets | ¥15,103 million |
| Net assets | ¥11,885 million |
| Full-year earnings forecast | Net Sales Undecided / Operating profit Undecided / Ordinary income Undecided / Net income Undecided |
| Annual Dividend Forecast | ¥3.00 → Undecided |
| Segment revenue | Pharmaceuticals ¥2,506,599 thousand (YoY +0.7%) / Healthcare Business ¥1,824,311 thousand (YoY +3.1%) / Global Business ¥1,342,022 thousand (YoY +12.0%) / Real estate leasing ¥133,938 thousand (YoY +4.2%) |
| Segment profit | Pharmaceuticals ¥-878,572 thousand / Healthcare Business ¥308,557 thousand / Global Business ¥182,205 thousand / Real estate leasing ¥46,245 thousand |
| Depreciation and amortization | ¥316,831 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥170,562 thousand / Extraordinary loss Loss on disposal of non-current assets ¥1,936 thousand, Office relocation expenses ¥1,314 thousand |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 34,838,325 shares |
| Treasury Shares at Period-End | 132,023 shares |
| Factors Behind Changes in Business Performance | 売上高は、医薬事業の製品供給停止等による減少があったものの、ジェネリック新製品の上市、ヘルスケア事業のブランド育成、グローバル事業の乳酸菌原料等の増加により増加した。営業損失の拡大は、人件費等の増加による販売費及び一般管理費の増加による。 |
Items this document does not state (13)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossChanges in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上高は、医薬事業の製品供給停止などによる減少があったものの、ジェネリック新製品の上市、ヘルスケア事業のブランド育成、グローバル事業の乳酸菌原料等の増加により増加した。営業損失の拡大は、人件費等の増加による販売費及び一般管理費の増加が主因であり、四半期純損失の縮小には法人税等調整額△1億2,400万円の計上が影響した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.